Dr. Beth Vasievich joined CARGO Therapeutics as Head of Commercial Planning and Operations in June 2023 bringing extensive cell therapy and commercialization experience through multiple oncology launches. At CARGO, Dr. Vasievich led the areas of market research, forecasting, competitive intelligence, commercial analytics, commercial operations, training and CARGO’s product delivery system. Previously, Dr. Vasievich was Vice President, Portfolio Strategy and Commercial Operations at Gamida Cell leading commercial planning and commercial operations for the launch of OMISIRGE (omidubicel-onlv), an advanced cell therapy for patients in need of an allogenic stem cell transplant, in addition to leading pipeline strategy for their NK cell therapies. Prior, she worked at Atara Biotherapeutics where she led commercial planning for the portfolio including the first approved allogenic T cell therapy, EBVALLO (tabelecleucel) and a pipeline of autologous and allogeneic chimeric antigen receptor T cell therapies (CAR-Ts). Dr. Vasievich spent eight years at Genentech / Roche in roles of increasing responsibility in global product strategy and commercialization, portfolio management, and business development, notably working on the global launches of TECENTRIQ, ZELBORAF and ERIVEDGE and development of Roche’s antibody drug conjugate (ADC) and cancer immunotherapy portfolios. Dr. Vasievich earned Bachelor of Science degrees in Biomedical Engineering, and Mechanical Engineering and Material Science, from Duke University and a PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill.